Printer Friendly

Threshold Pharmaceuticals wins two patents for Tarloxotinib Bromide in the US.

M2 EQUITYBITES-October 13, 2015-Threshold Pharmaceuticals wins two patents for Tarloxotinib Bromide in the US

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company Threshold Pharmaceuticals (NASDAQ:THLD) reported on Tuesday that it has been granted two patents protecting tarloxotinib bromide, or "tarloxotinib" by US Patent and Trademark Office (USPTO).

The company said tarloxotinib bromide, or "tarloxotinib," is its proprietary hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor exclusively licensed from the University of Auckland, New Zealand. Tarloxotinib bromide, or "tarloxotinib," is a prodrug designed to selectively release a covalent (irreversible) EGFR tyrosine kinase inhibitor under severe hypoxia, a feature of many solid tumors.

In addition, the company' first patent, which has been assigned the US Patent No. 9,073,916, generically covers a structural class of EGFR tyrosine kinase inhibitor prodrugs, including tarloxotinib, and pharmaceutical compositions containing this structural class of prodrugs.

Concurrently, the company's second patent, which has been assigned the US Patent No. 9,101,632, specifically covers the compound tarloxotinib and pharmaceutical compositions containing it.

These two patents provide fundamental intellectual property protection for tarloxotinib, which is the subject of two ongoing Phase 2 clinical trials for the treatment of patients with mutant EGFR-positive non-small cell lung cancer and patients with squamous cell cancers of the head and neck or skin, said its CEO Barry Selick, PhD.

According to the company, the most common type of lung cancer, non-small cell lung cancer (NSCLC), accounts for approximately 85% to 90% of cases. EGFR activating mutations occur in approximately 10% of NSCLC cases in Caucasian patients and up to 35% in Asian patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 13, 2015
Words:278
Previous Article:CME launches global physically delivered Lead futures contract in US and Europe.
Next Article:Consumers Energy anticipates lower heating costs this winter for natural gas customers.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters